Fabry disease treatment strategy
- Authors: Moiseev S.V1, Karovaikina E.A1, Bulanov N.M1, Moiseev A.S1,2, Fomin V.V1
-
Affiliations:
- I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
- M.V.Lomonosov Moscow State University
- Issue: Vol 20, No 12 (2018)
- Pages: 94-98
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95142
- DOI: https://doi.org/10.26442/20751753.2018.12.000001
- ID: 95142
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
S. V Moiseev
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Email: clinpharm@mtu-net.ru
д-р мед. наук, проф., зав. каф. внутренних, профессиональных болезней и ревматологии 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
E. A Karovaikina
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Email: karovaikinaea@gmail.com
мл. науч. сотр. НИО здоровьесберегающих технологий 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
N. M Bulanov
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Email: nmbulanov@gmail.com
канд. мед. наук, ассистент каф. внутренних, профессиональных болезней и ревматологии 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
A. S Moiseev
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation; M.V.Lomonosov Moscow State University
Email: moiseev7alexey@gmail.com
ординатор каф. внутренних болезней фак-та фундаментальной медицины 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2; 119991, Russian Federation, Moscow, Leninskie gory, d. 1
V. V Fomin
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federationчл.-кор. РАН, д-р мед. наук, проф., проректор по клинической работе и ДПО 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
References
- Zarate Y.A, Hopkin R.J. Fabry’s disease. Lancet 2008; 372 (9647): 1427-35.
- Popli S, Leehey D.J, Molnar Z.V et al. Demonstration of Fabry’s disease deposits in placenta. Am J Obstet Gynecol 1990; 162 (2): 464-5.
- Vedder A.C, Strijland A, vd Bergh Weerman M.A et al. Manifestations of Fabry disease in placental tissue. J Inherit Metab Dis 2006; 29 (1): 106-11.
- Hopkin R.J, Bissler J, Banikazemi M et al. Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry. Pediatr Res 2008; 64 (5): 550-5.
- Eng C.M, Fletcher J, Wilcox W.R et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007; 30 (2): 184-92.
- Schiffmann R, Kopp J.B, Austin H.A et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285 (21): 2743-9.
- Eng C.M, Guffon N, Wilcox R.W et al. Safety and efficacy of recombinant human a-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med 2001; 345 (1): 9-16.
- Wanner C, Arad M, Baron R et al. European expert consensus statement on therapeutic goals in Fabry disease. Mol Genet Metab 2018; 124 (3): 189-203.
- Beck M. Agalsidase alfa - a preparation for enzyme replacement therapy in Anderson-Fabry disease. Expert Opin Investig Drugs 2002; 11 (6): 851-8.
- Keating G.M, Simpson D. Agalsidase beta: A review of its use in the management of Fabry disease. Drugs 2007; 67 (3): 435-55.
- Germain D.P, Hughes D.A, Nicholls K et al. Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med 2016; 375 (6): 545-55.
- Hughes D.A, Nicholls K, Shankar S.P et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 2017; 54 (4): 288-96.
- Ortiz A, Germain D.P, Desnick R.J et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab 2018; 123: 416-27.
- Gibas A.L, Klatt R, Johnson J et al. A survey of the pain experienced by males and females with Fabry disease. Pain Res Manag 2006; 11 (3): 185-92.
- Hoffmann B, Beck M, Sunder-Plassmann G et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy - A retrospective analysis from the Fabry outcome survey. Clin J Pain 2007; 23 (6): 535-42.
- Üçeyler N, Ganendiran S, Kramer D et al. Characterization of pain in Fabry disease. Clin J Pain 2014; 30 (10): 915-20.
- Schiffmann R. Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy. Acta Neurol Belg 2006; 106 (2): 61-5.
- Biegstraaten M, Hollak CEM, Bakkers M et al. Small fiber neuropathy in Fabry disease. Mol Genet Metab 2012; 106 (2): 135-41.
- Üçeyler N, Magg B, Thomas P et al. A comprehensive Fabry-related pain questionnaire for adult patients. Pain 2014; 155 (11): 2301-5.
- Burlina A.P, Sims K.B, Politei J.M et al. Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: The report of an expert panel. BMC Neurol 2011; 11 (1): 61.
- National Institute for Health and Care Excellence. Neuropathic pain - pharmacological management. The pharmacological management of neuropathic pain in adults in non-specialist settings. NICE clinical guideline. 2013; p. 173.
- Schuller Y, Linthorst G.E, Hollak C.E.M et al. Pain management strategies for neuropathic pain in Fabry disease - a systematic review. BMC Neurol 2016; 16 (1): 25.
- Моисеев С.В., Новиков П.И., Фомин В.В. Лечение болезни Фабри. Клин. фармакология и терапия. 2016; 25 (4): 63-70.
- Linhart A, Kampmann C, Zamorano J.L et al. Cardiac manifestations of Anderson-Fabry disease: Results from the international Fabry outcome survey. Eur Heart J 2007; 28 (10): 1228-35.
- Kampmann C, Linhart A, Baehner F et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 2008; 130 (3): 367-73.
- Shah J.S, Hughes D.A, Sachdev B et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Dabry disease. Am J Cardiol 2005; 96 (6): 842-6.
- Weidemann F, Strotmann J.M, Niemann M et al. Heart Valve Involvement in Fabry Cardiomyopathy. Ultrasound Med Biol 2009; 35 (5): 730-5.
- Seydelmann N, Wanner C, Störk S et al. Fabry disease and the heart. Best Pract Res Clin Endocrinol Metab 2015; 29 (2): 195-204.
- Hughes D.A, Elliot P.M, Shah J et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008; 94 (2): 153-8.
- Imbriaco M, Pisani A, Spinelli L et al. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: A prospective longterm cardiac magnetic resonance imaging study. Heart 2009; 95 (13): 1103-7.
- Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment. Orphanet J Rare Dis 2015; 10 (1): 21-7.
- Weidemann F, Niemann M, Störk S et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: Evidence for disease progression towards serious complications. J Intern Med 2013; 274 (4): 331-41.
- Каровайкина Е.А., Моисеев С.В., Буланов Н.М. и др. Распространенность и основные проявления поражения почек у пациентов с болезнью Фабри. Клин. фармакология и терапия. 2018; 27 (4): 46-52.
- Fogo A.B, Bostad L, Svarstad E et al. Scoring system for renal pathology in Fabry disease: Report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 2010; 25 (7): 2168-77.
- MacDermot K.D, Holmes A, Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38 (11): 750-60.
- Schiffmann R, Warnock D.G, Banikazemi M et al. Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 2009; 24 (7): 2102-11.
- Warnock D.G, Ortiz A, Mauer M et al. Renal outcomes of agalsidase beta treatment for Fabry disease: Role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 2012; 27 (3): 1042-9.
- Arends M, Biegstraaten M, Hughes D.A et al. Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors. PLoS One 2017; 12 (8): e0182379.
- Wanner C, Oliveira J.P, Ortiz A et al. Prognostic indicators of renal disease progression in adults with fabry disease: Natural history data from the Fabry Registry. Clin J Am Soc Nephrol 2010; 5 (12): 2220-8.
- Warnock D.G, Thomas C.P, Vujkovac B et al. Antiproteinuric therapy and Fabry nephropathy: Factors associated with preserved kidney function during agalsidase-beta therapy. J Med Genet 2015; 52 (12): 860-6.
- Shah T, Gill J, Malhotra N et al. Kidney transplant outcomes in patients with Fabry disease. Transplantation 2009; 87 (2): 280-5.
- Talbot A.S, Lewis N.T, Nicholls K.M. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease. Heart 2015; 101 (4): 287-93.
- Sims K, Politei J, Banikazemi M et al. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: Natural history data from the Fabry registry. Stroke 2009; 40 (3): 788-94.
- Fellgiebel A, Gartenschläger M, Wildberger K et al. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease. Cerebrovasc Dis 2014; 38 (6): 448-56.
- Hoffmann B, Schwarz M, Mehta A et al. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 2007; 5 (12): 1447-53.
- Suntjens E.B, Smid B.E, Biegstraaten M et al. Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy. J Inherit Metab Dis 2015; 38 (2): 351-8.